Meeting
2011 ASCO Annual Meeting
Neoadjuvant ixabepilone/carboplatin/trastuzumab in HER2-positive locally advanced breast cancer: A Sarah Cannon Research Institute phase II trial.
Authors
J. D. Zubkus
Tennessee Oncology, Nashville, TN
J. D. Zubkus , D. B. Daniel , J. F. Eakle , R. G. Bechhold , M. Shastry , P. S. Tucker , H. A. Burris III, J. D. Hainsworth , D. A. Yardley
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer - HER2/ER
Track
Breast Cancer
Sub Track
HER2+
Clinical Trial Registration Number
NCT00821886
Citation
J Clin Oncol 29: 2011 (suppl; abstr 621)
Abstract #
621
Poster Bd #
11G
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Neoadjuvant TCH (docetaxel/darboplatin/trastuzumab) versus EC-TH (epirubicin/cyclophosphamide followed by docetaxel/ trastuzumab ) in patients with HER2-positive breast cancer (neoCARH): A randomised, open-label, multicenter, phase II trial.
First Author: Hong-Fei Gao
Poster
2013 ASCO Annual Meeting
Phase I/II study of neoadjuvant carboplatin, eribulin mesylate, and trastuzumab (ECH) for operable HER2 positive (HER2+) breast cancer.
First Author: Lee Steven Schwartzberg
First Author: Nicholas Patrick McAndrew
Poster
2021 ASCO Annual Meeting
Pyrotinib as neoadjuvant therapy for HER2+ breast cancer: A multicenter, randomized, controlled, phase II trial.
First Author: Xiaowen Ding